Navigation Links
GeneNews announces 2007 year end results
Date:3/26/2008

-

Proceeds from exercise of employee stock options - 165,410

Net proceeds from exercise of 2004 broker

warrants - 33,452

Proceeds of long-term debt 1,899,990 -

Repayment of long-term debt (268,316) (139,427)

-------------------------------------------------------------------------

Cash provided by financing activities 1,688,559 23,956,151

-------------------------------------------------------------------------

INVESTING ACTIVITIES

Short-term investment (400,000) -

Additions to property, plant and equipment (2,377,874) (784,113)

-------------------------------------------------------------------------

Cash used in investing activities (2,777,874) (784,113)

-------------------------------------------------------------------------

Net increase (decrease) in cash and cash

equivalents during the year (9,314,538) 15,912,686

Cash and cash equivalents, beginning of year 20,593,568 4,680,882

-------------------------------------------------------------------------

Cash and cash equivalents, end of year 11,279,030 20,593,568

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Cash and cash equivalents are comprised

of the following

Cash 6,152,694 294,578

Investment in money market fund 5,126,336 20,298,990

-------------------------------------------------------------------------

11,279,030 20,593,568

------------------------------------------------
'/>"/>

SOURCE GeneNews Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
4. GeneNews receives ISO 13485 accreditation
5. GeneNews selected to present late-breaking abstract at AACR Annual Meeting
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email: